nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—CYP2D6—Vinorelbine—ovarian cancer	0.0412	0.213	CbGbCtD
Etoricoxib—CYP3A4—Topotecan—ovarian cancer	0.0372	0.192	CbGbCtD
Etoricoxib—CYP2C9—Paclitaxel—ovarian cancer	0.0317	0.164	CbGbCtD
Etoricoxib—CYP3A4—Vinorelbine—ovarian cancer	0.0262	0.135	CbGbCtD
Etoricoxib—CYP3A4—Paclitaxel—ovarian cancer	0.0184	0.0951	CbGbCtD
Etoricoxib—CYP2D6—Doxorubicin—ovarian cancer	0.0156	0.0806	CbGbCtD
Etoricoxib—CYP3A4—Docetaxel—ovarian cancer	0.0133	0.0688	CbGbCtD
Etoricoxib—PTGS2—ovarian follicle—ovarian cancer	0.0122	0.165	CbGeAlD
Etoricoxib—CYP3A4—Doxorubicin—ovarian cancer	0.00992	0.0513	CbGbCtD
Etoricoxib—MAPK14—embryo—ovarian cancer	0.00574	0.0777	CbGeAlD
Etoricoxib—MAPK14—epithelium—ovarian cancer	0.00469	0.0634	CbGeAlD
Etoricoxib—MAPK14—uterine cervix—ovarian cancer	0.00465	0.0629	CbGeAlD
Etoricoxib—MAPK14—decidua—ovarian cancer	0.00443	0.0599	CbGeAlD
Etoricoxib—MAPK14—uterus—ovarian cancer	0.00387	0.0524	CbGeAlD
Etoricoxib—MAPK14—female reproductive system—ovarian cancer	0.00348	0.0471	CbGeAlD
Etoricoxib—MAPK14—bone marrow—ovarian cancer	0.00329	0.0445	CbGeAlD
Etoricoxib—MAPK14—female gonad—ovarian cancer	0.00317	0.0429	CbGeAlD
Etoricoxib—MAPK14—vagina—ovarian cancer	0.00315	0.0426	CbGeAlD
Etoricoxib—MAPK14—testis—ovarian cancer	0.00281	0.038	CbGeAlD
Etoricoxib—MAPK14—lymph node—ovarian cancer	0.00204	0.0276	CbGeAlD
Etoricoxib—PTGS2—myometrium—ovarian cancer	0.00172	0.0232	CbGeAlD
Etoricoxib—PTGS2—embryo—ovarian cancer	0.00165	0.0223	CbGeAlD
Etoricoxib—PTGS2—epithelium—ovarian cancer	0.00135	0.0182	CbGeAlD
Etoricoxib—CYP2C19—vagina—ovarian cancer	0.00134	0.0181	CbGeAlD
Etoricoxib—PTGS2—uterine cervix—ovarian cancer	0.00134	0.0181	CbGeAlD
Etoricoxib—PTGS2—endometrium—ovarian cancer	0.00121	0.0164	CbGeAlD
Etoricoxib—CYP2C9—female reproductive system—ovarian cancer	0.00115	0.0155	CbGeAlD
Etoricoxib—PTGS2—uterus—ovarian cancer	0.00111	0.0151	CbGeAlD
Etoricoxib—CYP2E1—female reproductive system—ovarian cancer	0.00109	0.0147	CbGeAlD
Etoricoxib—PTGS2—female reproductive system—ovarian cancer	0.001	0.0135	CbGeAlD
Etoricoxib—PTGS2—bone marrow—ovarian cancer	0.000945	0.0128	CbGeAlD
Etoricoxib—PTGS2—female gonad—ovarian cancer	0.000911	0.0123	CbGeAlD
Etoricoxib—PTGS2—vagina—ovarian cancer	0.000905	0.0123	CbGeAlD
Etoricoxib—CYP2E1—testis—ovarian cancer	0.000877	0.0119	CbGeAlD
Etoricoxib—CYP3A4—female reproductive system—ovarian cancer	0.000875	0.0118	CbGeAlD
Etoricoxib—CYP2D6—female reproductive system—ovarian cancer	0.000861	0.0116	CbGeAlD
Etoricoxib—CYP2D6—female gonad—ovarian cancer	0.000783	0.0106	CbGeAlD
Etoricoxib—CYP2D6—testis—ovarian cancer	0.000695	0.0094	CbGeAlD
Etoricoxib—PTGS2—lymph node—ovarian cancer	0.000586	0.00793	CbGeAlD
Etoricoxib—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000309	0.000718	CcSEcCtD
Etoricoxib—Muscular weakness—Doxorubicin—ovarian cancer	0.000309	0.000718	CcSEcCtD
Etoricoxib—Vomiting—Vinorelbine—ovarian cancer	0.000308	0.000715	CcSEcCtD
Etoricoxib—Rash—Vinorelbine—ovarian cancer	0.000305	0.000709	CcSEcCtD
Etoricoxib—Dermatitis—Vinorelbine—ovarian cancer	0.000305	0.000709	CcSEcCtD
Etoricoxib—Abdominal distension—Doxorubicin—ovarian cancer	0.000305	0.000709	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000304	0.000707	CcSEcCtD
Etoricoxib—Headache—Vinorelbine—ovarian cancer	0.000303	0.000705	CcSEcCtD
Etoricoxib—Palpitations—Docetaxel—ovarian cancer	0.000299	0.000694	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000299	0.000694	CcSEcCtD
Etoricoxib—Weight increased—Epirubicin—ovarian cancer	0.000298	0.000692	CcSEcCtD
Etoricoxib—Pancreatitis—Doxorubicin—ovarian cancer	0.000297	0.00069	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000297	0.000689	CcSEcCtD
Etoricoxib—Hyperglycaemia—Epirubicin—ovarian cancer	0.000295	0.000686	CcSEcCtD
Etoricoxib—Cough—Docetaxel—ovarian cancer	0.000295	0.000686	CcSEcCtD
Etoricoxib—Angina pectoris—Doxorubicin—ovarian cancer	0.000295	0.000686	CcSEcCtD
Etoricoxib—Insomnia—Paclitaxel—ovarian cancer	0.000294	0.000684	CcSEcCtD
Etoricoxib—Pneumonia—Epirubicin—ovarian cancer	0.000293	0.000682	CcSEcCtD
Etoricoxib—Hypertension—Docetaxel—ovarian cancer	0.000292	0.000678	CcSEcCtD
Etoricoxib—Infestation—Epirubicin—ovarian cancer	0.000292	0.000678	CcSEcCtD
Etoricoxib—Infestation NOS—Epirubicin—ovarian cancer	0.000292	0.000678	CcSEcCtD
Etoricoxib—Bronchitis—Doxorubicin—ovarian cancer	0.000291	0.000677	CcSEcCtD
Etoricoxib—Dyspnoea—Paclitaxel—ovarian cancer	0.00029	0.000675	CcSEcCtD
Etoricoxib—Somnolence—Paclitaxel—ovarian cancer	0.000289	0.000673	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000289	0.000672	CcSEcCtD
Etoricoxib—Arthralgia—Docetaxel—ovarian cancer	0.000288	0.000669	CcSEcCtD
Etoricoxib—Chest pain—Docetaxel—ovarian cancer	0.000288	0.000669	CcSEcCtD
Etoricoxib—Nausea—Vinorelbine—ovarian cancer	0.000287	0.000668	CcSEcCtD
Etoricoxib—Renal failure—Epirubicin—ovarian cancer	0.000287	0.000667	CcSEcCtD
Etoricoxib—Dyspepsia—Paclitaxel—ovarian cancer	0.000287	0.000666	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000286	0.000665	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000286	0.000664	CcSEcCtD
Etoricoxib—Stomatitis—Epirubicin—ovarian cancer	0.000284	0.000661	CcSEcCtD
Etoricoxib—Jaundice—Epirubicin—ovarian cancer	0.000284	0.000661	CcSEcCtD
Etoricoxib—Conjunctivitis—Epirubicin—ovarian cancer	0.000284	0.000659	CcSEcCtD
Etoricoxib—Urinary tract infection—Epirubicin—ovarian cancer	0.000284	0.000659	CcSEcCtD
Etoricoxib—Decreased appetite—Paclitaxel—ovarian cancer	0.000283	0.000658	CcSEcCtD
Etoricoxib—Dry mouth—Docetaxel—ovarian cancer	0.000281	0.000654	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000281	0.000654	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000281	0.000653	CcSEcCtD
Etoricoxib—Fatigue—Paclitaxel—ovarian cancer	0.000281	0.000652	CcSEcCtD
Etoricoxib—Pain—Paclitaxel—ovarian cancer	0.000278	0.000647	CcSEcCtD
Etoricoxib—Constipation—Paclitaxel—ovarian cancer	0.000278	0.000647	CcSEcCtD
Etoricoxib—Haematuria—Epirubicin—ovarian cancer	0.000278	0.000647	CcSEcCtD
Etoricoxib—Confusional state—Docetaxel—ovarian cancer	0.000278	0.000647	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000276	0.000642	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000276	0.000641	CcSEcCtD
Etoricoxib—Oedema—Docetaxel—ovarian cancer	0.000276	0.000641	CcSEcCtD
Etoricoxib—Anaphylactic shock—Docetaxel—ovarian cancer	0.000276	0.000641	CcSEcCtD
Etoricoxib—Weight increased—Doxorubicin—ovarian cancer	0.000276	0.000641	CcSEcCtD
Etoricoxib—Epistaxis—Epirubicin—ovarian cancer	0.000275	0.00064	CcSEcCtD
Etoricoxib—Infection—Docetaxel—ovarian cancer	0.000274	0.000637	CcSEcCtD
Etoricoxib—Sinusitis—Epirubicin—ovarian cancer	0.000274	0.000636	CcSEcCtD
Etoricoxib—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000273	0.000635	CcSEcCtD
Etoricoxib—Pneumonia—Doxorubicin—ovarian cancer	0.000272	0.000631	CcSEcCtD
Etoricoxib—Shock—Docetaxel—ovarian cancer	0.000271	0.000631	CcSEcCtD
Etoricoxib—Nervous system disorder—Docetaxel—ovarian cancer	0.000271	0.000629	CcSEcCtD
Etoricoxib—Thrombocytopenia—Docetaxel—ovarian cancer	0.00027	0.000628	CcSEcCtD
Etoricoxib—Infestation—Doxorubicin—ovarian cancer	0.00027	0.000628	CcSEcCtD
Etoricoxib—Infestation NOS—Doxorubicin—ovarian cancer	0.00027	0.000628	CcSEcCtD
Etoricoxib—Feeling abnormal—Paclitaxel—ovarian cancer	0.000268	0.000624	CcSEcCtD
Etoricoxib—Skin disorder—Docetaxel—ovarian cancer	0.000268	0.000623	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000268	0.000622	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000266	0.000619	CcSEcCtD
Etoricoxib—Renal failure—Doxorubicin—ovarian cancer	0.000265	0.000617	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000265	0.000615	CcSEcCtD
Etoricoxib—Haemoglobin—Epirubicin—ovarian cancer	0.000263	0.000612	CcSEcCtD
Etoricoxib—Stomatitis—Doxorubicin—ovarian cancer	0.000263	0.000612	CcSEcCtD
Etoricoxib—Jaundice—Doxorubicin—ovarian cancer	0.000263	0.000612	CcSEcCtD
Etoricoxib—Anorexia—Docetaxel—ovarian cancer	0.000263	0.000611	CcSEcCtD
Etoricoxib—Conjunctivitis—Doxorubicin—ovarian cancer	0.000262	0.00061	CcSEcCtD
Etoricoxib—Urinary tract infection—Doxorubicin—ovarian cancer	0.000262	0.00061	CcSEcCtD
Etoricoxib—Hepatitis—Epirubicin—ovarian cancer	0.000262	0.000609	CcSEcCtD
Etoricoxib—Haemorrhage—Epirubicin—ovarian cancer	0.000262	0.000609	CcSEcCtD
Etoricoxib—Hypoaesthesia—Epirubicin—ovarian cancer	0.000261	0.000606	CcSEcCtD
Etoricoxib—Pharyngitis—Epirubicin—ovarian cancer	0.00026	0.000604	CcSEcCtD
Etoricoxib—Urinary tract disorder—Epirubicin—ovarian cancer	0.000259	0.000601	CcSEcCtD
Etoricoxib—Urticaria—Paclitaxel—ovarian cancer	0.000259	0.000601	CcSEcCtD
Etoricoxib—Oedema peripheral—Epirubicin—ovarian cancer	0.000258	0.0006	CcSEcCtD
Etoricoxib—Haematuria—Doxorubicin—ovarian cancer	0.000257	0.000598	CcSEcCtD
Etoricoxib—Connective tissue disorder—Epirubicin—ovarian cancer	0.000257	0.000598	CcSEcCtD
Etoricoxib—Abdominal pain—Paclitaxel—ovarian cancer	0.000257	0.000598	CcSEcCtD
Etoricoxib—Urethral disorder—Epirubicin—ovarian cancer	0.000257	0.000597	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000255	0.000594	CcSEcCtD
Etoricoxib—Epistaxis—Doxorubicin—ovarian cancer	0.000255	0.000592	CcSEcCtD
Etoricoxib—Sinusitis—Doxorubicin—ovarian cancer	0.000253	0.000589	CcSEcCtD
Etoricoxib—Visual impairment—Epirubicin—ovarian cancer	0.000252	0.000587	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000251	0.000584	CcSEcCtD
Etoricoxib—Insomnia—Docetaxel—ovarian cancer	0.00025	0.00058	CcSEcCtD
Etoricoxib—Erythema multiforme—Epirubicin—ovarian cancer	0.000248	0.000576	CcSEcCtD
Etoricoxib—Dyspnoea—Docetaxel—ovarian cancer	0.000246	0.000572	CcSEcCtD
Etoricoxib—Somnolence—Docetaxel—ovarian cancer	0.000245	0.00057	CcSEcCtD
Etoricoxib—Eye disorder—Epirubicin—ovarian cancer	0.000245	0.000569	CcSEcCtD
Etoricoxib—Tinnitus—Epirubicin—ovarian cancer	0.000244	0.000568	CcSEcCtD
Etoricoxib—Haemoglobin—Doxorubicin—ovarian cancer	0.000244	0.000566	CcSEcCtD
Etoricoxib—Flushing—Epirubicin—ovarian cancer	0.000243	0.000565	CcSEcCtD
Etoricoxib—Cardiac disorder—Epirubicin—ovarian cancer	0.000243	0.000565	CcSEcCtD
Etoricoxib—Dyspepsia—Docetaxel—ovarian cancer	0.000243	0.000565	CcSEcCtD
Etoricoxib—Haemorrhage—Doxorubicin—ovarian cancer	0.000242	0.000563	CcSEcCtD
Etoricoxib—Hepatitis—Doxorubicin—ovarian cancer	0.000242	0.000563	CcSEcCtD
Etoricoxib—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000241	0.000561	CcSEcCtD
Etoricoxib—Pharyngitis—Doxorubicin—ovarian cancer	0.000241	0.000559	CcSEcCtD
Etoricoxib—Decreased appetite—Docetaxel—ovarian cancer	0.00024	0.000558	CcSEcCtD
Etoricoxib—Hypersensitivity—Paclitaxel—ovarian cancer	0.00024	0.000557	CcSEcCtD
Etoricoxib—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000239	0.000556	CcSEcCtD
Etoricoxib—Oedema peripheral—Doxorubicin—ovarian cancer	0.000239	0.000555	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000238	0.000554	CcSEcCtD
Etoricoxib—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000238	0.000554	CcSEcCtD
Etoricoxib—Fatigue—Docetaxel—ovarian cancer	0.000238	0.000553	CcSEcCtD
Etoricoxib—Angiopathy—Epirubicin—ovarian cancer	0.000238	0.000552	CcSEcCtD
Etoricoxib—Urethral disorder—Doxorubicin—ovarian cancer	0.000238	0.000552	CcSEcCtD
Etoricoxib—Immune system disorder—Epirubicin—ovarian cancer	0.000237	0.00055	CcSEcCtD
Etoricoxib—Mediastinal disorder—Epirubicin—ovarian cancer	0.000236	0.000549	CcSEcCtD
Etoricoxib—Constipation—Docetaxel—ovarian cancer	0.000236	0.000548	CcSEcCtD
Etoricoxib—Pain—Docetaxel—ovarian cancer	0.000236	0.000548	CcSEcCtD
Etoricoxib—Arrhythmia—Epirubicin—ovarian cancer	0.000234	0.000544	CcSEcCtD
Etoricoxib—Visual impairment—Doxorubicin—ovarian cancer	0.000234	0.000543	CcSEcCtD
Etoricoxib—Asthenia—Paclitaxel—ovarian cancer	0.000234	0.000543	CcSEcCtD
Etoricoxib—Alopecia—Epirubicin—ovarian cancer	0.000231	0.000538	CcSEcCtD
Etoricoxib—Pruritus—Paclitaxel—ovarian cancer	0.00023	0.000535	CcSEcCtD
Etoricoxib—Mental disorder—Epirubicin—ovarian cancer	0.000229	0.000533	CcSEcCtD
Etoricoxib—Erythema multiforme—Doxorubicin—ovarian cancer	0.000229	0.000533	CcSEcCtD
Etoricoxib—Erythema—Epirubicin—ovarian cancer	0.000228	0.00053	CcSEcCtD
Etoricoxib—Malnutrition—Epirubicin—ovarian cancer	0.000228	0.00053	CcSEcCtD
Etoricoxib—Feeling abnormal—Docetaxel—ovarian cancer	0.000227	0.000528	CcSEcCtD
Etoricoxib—Eye disorder—Doxorubicin—ovarian cancer	0.000226	0.000526	CcSEcCtD
Etoricoxib—Tinnitus—Doxorubicin—ovarian cancer	0.000226	0.000525	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000226	0.000524	CcSEcCtD
Etoricoxib—Cardiac disorder—Doxorubicin—ovarian cancer	0.000225	0.000523	CcSEcCtD
Etoricoxib—Flushing—Doxorubicin—ovarian cancer	0.000225	0.000523	CcSEcCtD
Etoricoxib—Flatulence—Epirubicin—ovarian cancer	0.000225	0.000522	CcSEcCtD
Etoricoxib—Dysgeusia—Epirubicin—ovarian cancer	0.000223	0.000519	CcSEcCtD
Etoricoxib—Diarrhoea—Paclitaxel—ovarian cancer	0.000223	0.000518	CcSEcCtD
Etoricoxib—Angiopathy—Doxorubicin—ovarian cancer	0.00022	0.000511	CcSEcCtD
Etoricoxib—Muscle spasms—Epirubicin—ovarian cancer	0.000219	0.00051	CcSEcCtD
Etoricoxib—Immune system disorder—Doxorubicin—ovarian cancer	0.000219	0.000509	CcSEcCtD
Etoricoxib—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000218	0.000508	CcSEcCtD
Etoricoxib—Abdominal pain—Docetaxel—ovarian cancer	0.000218	0.000507	CcSEcCtD
Etoricoxib—Arrhythmia—Doxorubicin—ovarian cancer	0.000217	0.000503	CcSEcCtD
Etoricoxib—Dizziness—Paclitaxel—ovarian cancer	0.000215	0.0005	CcSEcCtD
Etoricoxib—Vision blurred—Epirubicin—ovarian cancer	0.000215	0.0005	CcSEcCtD
Etoricoxib—Alopecia—Doxorubicin—ovarian cancer	0.000214	0.000498	CcSEcCtD
Etoricoxib—Mental disorder—Doxorubicin—ovarian cancer	0.000212	0.000494	CcSEcCtD
Etoricoxib—Malnutrition—Doxorubicin—ovarian cancer	0.000211	0.00049	CcSEcCtD
Etoricoxib—Erythema—Doxorubicin—ovarian cancer	0.000211	0.00049	CcSEcCtD
Etoricoxib—Anaemia—Epirubicin—ovarian cancer	0.000211	0.00049	CcSEcCtD
Etoricoxib—Agitation—Epirubicin—ovarian cancer	0.00021	0.000487	CcSEcCtD
Etoricoxib—Flatulence—Doxorubicin—ovarian cancer	0.000208	0.000483	CcSEcCtD
Etoricoxib—Vomiting—Paclitaxel—ovarian cancer	0.000207	0.000481	CcSEcCtD
Etoricoxib—Dysgeusia—Doxorubicin—ovarian cancer	0.000207	0.00048	CcSEcCtD
Etoricoxib—Rash—Paclitaxel—ovarian cancer	0.000205	0.000477	CcSEcCtD
Etoricoxib—Dermatitis—Paclitaxel—ovarian cancer	0.000205	0.000477	CcSEcCtD
Etoricoxib—Headache—Paclitaxel—ovarian cancer	0.000204	0.000474	CcSEcCtD
Etoricoxib—Hypersensitivity—Docetaxel—ovarian cancer	0.000203	0.000473	CcSEcCtD
Etoricoxib—Muscle spasms—Doxorubicin—ovarian cancer	0.000203	0.000472	CcSEcCtD
Etoricoxib—Palpitations—Epirubicin—ovarian cancer	0.000201	0.000468	CcSEcCtD
Etoricoxib—Cough—Epirubicin—ovarian cancer	0.000199	0.000463	CcSEcCtD
Etoricoxib—Vision blurred—Doxorubicin—ovarian cancer	0.000199	0.000462	CcSEcCtD
Etoricoxib—Asthenia—Docetaxel—ovarian cancer	0.000198	0.00046	CcSEcCtD
Etoricoxib—Hypertension—Epirubicin—ovarian cancer	0.000197	0.000458	CcSEcCtD
Etoricoxib—Pruritus—Docetaxel—ovarian cancer	0.000195	0.000454	CcSEcCtD
Etoricoxib—Anaemia—Doxorubicin—ovarian cancer	0.000195	0.000453	CcSEcCtD
Etoricoxib—Chest pain—Epirubicin—ovarian cancer	0.000194	0.000451	CcSEcCtD
Etoricoxib—Arthralgia—Epirubicin—ovarian cancer	0.000194	0.000451	CcSEcCtD
Etoricoxib—Agitation—Doxorubicin—ovarian cancer	0.000194	0.000451	CcSEcCtD
Etoricoxib—Anxiety—Epirubicin—ovarian cancer	0.000193	0.00045	CcSEcCtD
Etoricoxib—Nausea—Paclitaxel—ovarian cancer	0.000193	0.000449	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000193	0.000448	CcSEcCtD
Etoricoxib—Dry mouth—Epirubicin—ovarian cancer	0.00019	0.000441	CcSEcCtD
Etoricoxib—Diarrhoea—Docetaxel—ovarian cancer	0.000189	0.000439	CcSEcCtD
Etoricoxib—Confusional state—Epirubicin—ovarian cancer	0.000188	0.000436	CcSEcCtD
Etoricoxib—Palpitations—Doxorubicin—ovarian cancer	0.000186	0.000433	CcSEcCtD
Etoricoxib—Anaphylactic shock—Epirubicin—ovarian cancer	0.000186	0.000433	CcSEcCtD
Etoricoxib—Oedema—Epirubicin—ovarian cancer	0.000186	0.000433	CcSEcCtD
Etoricoxib—Infection—Epirubicin—ovarian cancer	0.000185	0.00043	CcSEcCtD
Etoricoxib—Cough—Doxorubicin—ovarian cancer	0.000184	0.000428	CcSEcCtD
Etoricoxib—Shock—Epirubicin—ovarian cancer	0.000183	0.000426	CcSEcCtD
Etoricoxib—Nervous system disorder—Epirubicin—ovarian cancer	0.000182	0.000424	CcSEcCtD
Etoricoxib—Dizziness—Docetaxel—ovarian cancer	0.000182	0.000424	CcSEcCtD
Etoricoxib—Thrombocytopenia—Epirubicin—ovarian cancer	0.000182	0.000424	CcSEcCtD
Etoricoxib—Hypertension—Doxorubicin—ovarian cancer	0.000182	0.000423	CcSEcCtD
Etoricoxib—Skin disorder—Epirubicin—ovarian cancer	0.000181	0.00042	CcSEcCtD
Etoricoxib—Arthralgia—Doxorubicin—ovarian cancer	0.00018	0.000418	CcSEcCtD
Etoricoxib—Chest pain—Doxorubicin—ovarian cancer	0.00018	0.000418	CcSEcCtD
Etoricoxib—Anxiety—Doxorubicin—ovarian cancer	0.000179	0.000416	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000178	0.000415	CcSEcCtD
Etoricoxib—Anorexia—Epirubicin—ovarian cancer	0.000177	0.000412	CcSEcCtD
Etoricoxib—Dry mouth—Doxorubicin—ovarian cancer	0.000176	0.000408	CcSEcCtD
Etoricoxib—Vomiting—Docetaxel—ovarian cancer	0.000175	0.000408	CcSEcCtD
Etoricoxib—Rash—Docetaxel—ovarian cancer	0.000174	0.000404	CcSEcCtD
Etoricoxib—Dermatitis—Docetaxel—ovarian cancer	0.000174	0.000404	CcSEcCtD
Etoricoxib—Confusional state—Doxorubicin—ovarian cancer	0.000174	0.000404	CcSEcCtD
Etoricoxib—Headache—Docetaxel—ovarian cancer	0.000173	0.000402	CcSEcCtD
Etoricoxib—Oedema—Doxorubicin—ovarian cancer	0.000172	0.0004	CcSEcCtD
Etoricoxib—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000172	0.0004	CcSEcCtD
Etoricoxib—Infection—Doxorubicin—ovarian cancer	0.000171	0.000398	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.00017	0.000394	CcSEcCtD
Etoricoxib—Shock—Doxorubicin—ovarian cancer	0.000169	0.000394	CcSEcCtD
Etoricoxib—Nervous system disorder—Doxorubicin—ovarian cancer	0.000169	0.000393	CcSEcCtD
Etoricoxib—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000169	0.000392	CcSEcCtD
Etoricoxib—Insomnia—Epirubicin—ovarian cancer	0.000168	0.000391	CcSEcCtD
Etoricoxib—Skin disorder—Doxorubicin—ovarian cancer	0.000167	0.000389	CcSEcCtD
Etoricoxib—Dyspnoea—Epirubicin—ovarian cancer	0.000166	0.000386	CcSEcCtD
Etoricoxib—Somnolence—Epirubicin—ovarian cancer	0.000165	0.000385	CcSEcCtD
Etoricoxib—Anorexia—Doxorubicin—ovarian cancer	0.000164	0.000382	CcSEcCtD
Etoricoxib—Nausea—Docetaxel—ovarian cancer	0.000164	0.000381	CcSEcCtD
Etoricoxib—Dyspepsia—Epirubicin—ovarian cancer	0.000164	0.000381	CcSEcCtD
Etoricoxib—Decreased appetite—Epirubicin—ovarian cancer	0.000162	0.000376	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000161	0.000373	CcSEcCtD
Etoricoxib—Fatigue—Epirubicin—ovarian cancer	0.00016	0.000373	CcSEcCtD
Etoricoxib—Pain—Epirubicin—ovarian cancer	0.000159	0.00037	CcSEcCtD
Etoricoxib—Constipation—Epirubicin—ovarian cancer	0.000159	0.00037	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000157	0.000365	CcSEcCtD
Etoricoxib—Insomnia—Doxorubicin—ovarian cancer	0.000156	0.000362	CcSEcCtD
Etoricoxib—Dyspnoea—Doxorubicin—ovarian cancer	0.000154	0.000357	CcSEcCtD
Etoricoxib—Feeling abnormal—Epirubicin—ovarian cancer	0.000153	0.000356	CcSEcCtD
Etoricoxib—Somnolence—Doxorubicin—ovarian cancer	0.000153	0.000356	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000152	0.000354	CcSEcCtD
Etoricoxib—Dyspepsia—Doxorubicin—ovarian cancer	0.000152	0.000352	CcSEcCtD
Etoricoxib—Decreased appetite—Doxorubicin—ovarian cancer	0.00015	0.000348	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000149	0.000346	CcSEcCtD
Etoricoxib—Fatigue—Doxorubicin—ovarian cancer	0.000148	0.000345	CcSEcCtD
Etoricoxib—Urticaria—Epirubicin—ovarian cancer	0.000148	0.000344	CcSEcCtD
Etoricoxib—Pain—Doxorubicin—ovarian cancer	0.000147	0.000342	CcSEcCtD
Etoricoxib—Constipation—Doxorubicin—ovarian cancer	0.000147	0.000342	CcSEcCtD
Etoricoxib—Abdominal pain—Epirubicin—ovarian cancer	0.000147	0.000342	CcSEcCtD
Etoricoxib—Feeling abnormal—Doxorubicin—ovarian cancer	0.000142	0.00033	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000141	0.000327	CcSEcCtD
Etoricoxib—Hypersensitivity—Epirubicin—ovarian cancer	0.000137	0.000319	CcSEcCtD
Etoricoxib—Urticaria—Doxorubicin—ovarian cancer	0.000137	0.000318	CcSEcCtD
Etoricoxib—Abdominal pain—Doxorubicin—ovarian cancer	0.000136	0.000316	CcSEcCtD
Etoricoxib—Asthenia—Epirubicin—ovarian cancer	0.000134	0.00031	CcSEcCtD
Etoricoxib—Pruritus—Epirubicin—ovarian cancer	0.000132	0.000306	CcSEcCtD
Etoricoxib—Diarrhoea—Epirubicin—ovarian cancer	0.000127	0.000296	CcSEcCtD
Etoricoxib—Hypersensitivity—Doxorubicin—ovarian cancer	0.000127	0.000295	CcSEcCtD
Etoricoxib—Asthenia—Doxorubicin—ovarian cancer	0.000124	0.000287	CcSEcCtD
Etoricoxib—Dizziness—Epirubicin—ovarian cancer	0.000123	0.000286	CcSEcCtD
Etoricoxib—Pruritus—Doxorubicin—ovarian cancer	0.000122	0.000283	CcSEcCtD
Etoricoxib—Vomiting—Epirubicin—ovarian cancer	0.000118	0.000275	CcSEcCtD
Etoricoxib—Diarrhoea—Doxorubicin—ovarian cancer	0.000118	0.000274	CcSEcCtD
Etoricoxib—Rash—Epirubicin—ovarian cancer	0.000117	0.000273	CcSEcCtD
Etoricoxib—Dermatitis—Epirubicin—ovarian cancer	0.000117	0.000272	CcSEcCtD
Etoricoxib—Headache—Epirubicin—ovarian cancer	0.000117	0.000271	CcSEcCtD
Etoricoxib—Dizziness—Doxorubicin—ovarian cancer	0.000114	0.000265	CcSEcCtD
Etoricoxib—Nausea—Epirubicin—ovarian cancer	0.000111	0.000257	CcSEcCtD
Etoricoxib—Vomiting—Doxorubicin—ovarian cancer	0.000109	0.000254	CcSEcCtD
Etoricoxib—Rash—Doxorubicin—ovarian cancer	0.000109	0.000252	CcSEcCtD
Etoricoxib—Dermatitis—Doxorubicin—ovarian cancer	0.000108	0.000252	CcSEcCtD
Etoricoxib—Headache—Doxorubicin—ovarian cancer	0.000108	0.000251	CcSEcCtD
Etoricoxib—Nausea—Doxorubicin—ovarian cancer	0.000102	0.000238	CcSEcCtD
Etoricoxib—MAPK14—Developmental Biology—NRAS—ovarian cancer	4.8e-05	0.000159	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—VEGFA—ovarian cancer	4.77e-05	0.000158	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—PTEN—ovarian cancer	4.75e-05	0.000157	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—NRAS—ovarian cancer	4.71e-05	0.000156	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—YAP1—ovarian cancer	4.69e-05	0.000155	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PPP1CC—ovarian cancer	4.67e-05	0.000154	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—BRIP1—ovarian cancer	4.67e-05	0.000154	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	4.64e-05	0.000153	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—BRIP1—ovarian cancer	4.63e-05	0.000153	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PPP1CC—ovarian cancer	4.63e-05	0.000153	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—MAPK3—ovarian cancer	4.6e-05	0.000152	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—FASN—ovarian cancer	4.56e-05	0.000151	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PARP1—ovarian cancer	4.54e-05	0.00015	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—TLR4—ovarian cancer	4.54e-05	0.00015	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYTB—ovarian cancer	4.52e-05	0.00015	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—MAPK3—ovarian cancer	4.51e-05	0.000149	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.42e-05	0.000146	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—YAP1—ovarian cancer	4.41e-05	0.000146	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—ESR1—ovarian cancer	4.4e-05	0.000145	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—MAPK1—ovarian cancer	4.38e-05	0.000145	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—EGFR—ovarian cancer	4.37e-05	0.000145	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL6ST—ovarian cancer	4.35e-05	0.000144	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—SLC2A1—ovarian cancer	4.33e-05	0.000143	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—MAPK1—ovarian cancer	4.29e-05	0.000142	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—NRAS—ovarian cancer	4.24e-05	0.00014	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	4.24e-05	0.00014	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—KRAS—ovarian cancer	4.13e-05	0.000137	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	4.08e-05	0.000135	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—MAPK3—ovarian cancer	4.06e-05	0.000134	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—KRAS—ovarian cancer	4.05e-05	0.000134	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PPP2R1A—ovarian cancer	4.04e-05	0.000134	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PPP1CC—ovarian cancer	3.95e-05	0.000131	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—BRIP1—ovarian cancer	3.95e-05	0.000131	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—MAPK1—ovarian cancer	3.86e-05	0.000128	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—EGFR—ovarian cancer	3.86e-05	0.000128	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CDH1—ovarian cancer	3.85e-05	0.000127	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—FASN—ovarian cancer	3.82e-05	0.000126	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—SLC5A5—ovarian cancer	3.76e-05	0.000124	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—PIK3CA—ovarian cancer	3.72e-05	0.000123	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.7e-05	0.000122	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PPP2R1A—ovarian cancer	3.68e-05	0.000122	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PIK3CD—ovarian cancer	3.68e-05	0.000122	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—KRAS—ovarian cancer	3.65e-05	0.000121	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—SLC2A1—ovarian cancer	3.63e-05	0.00012	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—TP53—ovarian cancer	3.6e-05	0.000119	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—FASN—ovarian cancer	3.6e-05	0.000119	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.55e-05	0.000118	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—SLC5A5—ovarian cancer	3.54e-05	0.000117	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—HRAS—ovarian cancer	3.51e-05	0.000116	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYTB—ovarian cancer	3.49e-05	0.000115	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CYP1B1—ovarian cancer	3.48e-05	0.000115	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—HRAS—ovarian cancer	3.45e-05	0.000114	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—SLC2A1—ovarian cancer	3.42e-05	0.000113	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—YAP1—ovarian cancer	3.4e-05	0.000113	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.37e-05	0.000111	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.37e-05	0.000111	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—IL6—ovarian cancer	3.36e-05	0.000111	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—PIK3CA—ovarian cancer	3.35e-05	0.000111	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CYP1B1—ovarian cancer	3.28e-05	0.000108	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—ERBB2—ovarian cancer	3.25e-05	0.000107	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TERT—ovarian cancer	3.21e-05	0.000106	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PIK3CB—ovarian cancer	3.2e-05	0.000106	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—MTOR—ovarian cancer	3.2e-05	0.000106	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—YAP1—ovarian cancer	3.13e-05	0.000104	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—YAP1—ovarian cancer	3.1e-05	0.000103	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—HRAS—ovarian cancer	3.1e-05	0.000103	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—AKT1—ovarian cancer	3.1e-05	0.000103	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PPP2R1A—ovarian cancer	3.09e-05	0.000102	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.07e-05	0.000102	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.07e-05	0.000102	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—BRIP1—ovarian cancer	3.05e-05	0.000101	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PPP1CC—ovarian cancer	3.05e-05	0.000101	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—AKT1—ovarian cancer	3.04e-05	0.000101	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CDKN1B—ovarian cancer	3.01e-05	9.94e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—IL6—ovarian cancer	2.97e-05	9.82e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CAV1—ovarian cancer	2.97e-05	9.81e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.96e-05	9.79e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL2—ovarian cancer	2.94e-05	9.73e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—TERT—ovarian cancer	2.93e-05	9.68e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PPP2R1A—ovarian cancer	2.9e-05	9.61e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.88e-05	9.53e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ABCB1—ovarian cancer	2.87e-05	9.47e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—ESR1—ovarian cancer	2.86e-05	9.46e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CTNNB1—ovarian cancer	2.84e-05	9.39e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—TYMS—ovarian cancer	2.81e-05	9.31e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL6ST—ovarian cancer	2.81e-05	9.3e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—FASN—ovarian cancer	2.77e-05	9.17e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PTEN—ovarian cancer	2.77e-05	9.16e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—AKT1—ovarian cancer	2.74e-05	9.06e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—SLC5A5—ovarian cancer	2.73e-05	9.02e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CAV1—ovarian cancer	2.71e-05	8.95e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—APC—ovarian cancer	2.7e-05	8.94e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CG—ovarian cancer	2.7e-05	8.94e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.7e-05	8.93e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ABCB1—ovarian cancer	2.7e-05	8.92e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—YAP1—ovarian cancer	2.65e-05	8.77e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—TYMS—ovarian cancer	2.65e-05	8.76e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—SLC2A1—ovarian cancer	2.64e-05	8.72e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.62e-05	8.68e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.58e-05	8.53e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—IL6ST—ovarian cancer	2.57e-05	8.49e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—FASN—ovarian cancer	2.55e-05	8.44e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—FASN—ovarian cancer	2.53e-05	8.37e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CYP1B1—ovarian cancer	2.53e-05	8.36e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—SLC5A5—ovarian cancer	2.51e-05	8.3e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—SLC5A5—ovarian cancer	2.49e-05	8.23e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—STAT3—ovarian cancer	2.48e-05	8.19e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—NRAS—ovarian cancer	2.47e-05	8.17e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—APC—ovarian cancer	2.47e-05	8.16e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—SLC2A1—ovarian cancer	2.42e-05	8.02e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—SLC2A1—ovarian cancer	2.4e-05	7.95e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CD—ovarian cancer	2.38e-05	7.86e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—MAPK3—ovarian cancer	2.37e-05	7.82e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.35e-05	7.78e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—MAPK3—ovarian cancer	2.35e-05	7.78e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CYP1B1—ovarian cancer	2.32e-05	7.69e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.31e-05	7.63e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CYP1B1—ovarian cancer	2.3e-05	7.62e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—MYC—ovarian cancer	2.29e-05	7.57e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CAV1—ovarian cancer	2.27e-05	7.5e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—MAPK1—ovarian cancer	2.25e-05	7.44e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—EGFR—ovarian cancer	2.25e-05	7.44e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	2.24e-05	7.41e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.23e-05	7.37e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CD—ovarian cancer	2.17e-05	7.17e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.17e-05	7.16e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—FASN—ovarian cancer	2.16e-05	7.15e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CAV1—ovarian cancer	2.13e-05	7.06e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—SLC5A5—ovarian cancer	2.13e-05	7.03e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—KRAS—ovarian cancer	2.13e-05	7.03e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—ERBB2—ovarian cancer	2.1e-05	6.94e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ABCB1—ovarian cancer	2.08e-05	6.88e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MTOR—ovarian cancer	2.07e-05	6.85e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CB—ovarian cancer	2.07e-05	6.85e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CG—ovarian cancer	2.07e-05	6.83e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	2.06e-05	6.82e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—SLC2A1—ovarian cancer	2.05e-05	6.79e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—YAP1—ovarian cancer	2.05e-05	6.77e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—TYMS—ovarian cancer	2.04e-05	6.76e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	2.04e-05	6.76e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.03e-05	6.72e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.01e-05	6.65e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CXCL8—ovarian cancer	1.99e-05	6.58e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP1B1—ovarian cancer	1.97e-05	6.51e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PIK3CA—ovarian cancer	1.95e-05	6.46e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CG—ovarian cancer	1.94e-05	6.43e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CDKN1B—ovarian cancer	1.94e-05	6.43e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—ERBB2—ovarian cancer	1.91e-05	6.33e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ABCB1—ovarian cancer	1.91e-05	6.33e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CASP3—ovarian cancer	1.91e-05	6.3e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL2—ovarian cancer	1.9e-05	6.29e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ABCB1—ovarian cancer	1.9e-05	6.27e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CB—ovarian cancer	1.89e-05	6.25e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MTOR—ovarian cancer	1.89e-05	6.25e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—TYMS—ovarian cancer	1.88e-05	6.22e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—TYMS—ovarian cancer	1.86e-05	6.16e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCND1—ovarian cancer	1.85e-05	6.13e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CTNNB1—ovarian cancer	1.84e-05	6.07e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CD—ovarian cancer	1.82e-05	6e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HRAS—ovarian cancer	1.81e-05	5.98e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MMP9—ovarian cancer	1.8e-05	5.95e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PTEN—ovarian cancer	1.79e-05	5.92e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CDKN1B—ovarian cancer	1.77e-05	5.86e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	1.75e-05	5.77e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.74e-05	5.75e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL6—ovarian cancer	1.73e-05	5.72e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CD—ovarian cancer	1.71e-05	5.65e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CTNNB1—ovarian cancer	1.68e-05	5.54e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—FASN—ovarian cancer	1.67e-05	5.52e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CAV1—ovarian cancer	1.65e-05	5.45e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.64e-05	5.43e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PTEN—ovarian cancer	1.63e-05	5.4e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ABCB1—ovarian cancer	1.62e-05	5.36e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—VEGFA—ovarian cancer	1.62e-05	5.35e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—STAT3—ovarian cancer	1.6e-05	5.29e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NRAS—ovarian cancer	1.6e-05	5.28e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—AKT1—ovarian cancer	1.6e-05	5.28e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—TYMS—ovarian cancer	1.59e-05	5.27e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—AKT1—ovarian cancer	1.59e-05	5.25e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.59e-05	5.24e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CB—ovarian cancer	1.58e-05	5.23e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.57e-05	5.2e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MAPK3—ovarian cancer	1.53e-05	5.06e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.52e-05	5.03e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CAV1—ovarian cancer	1.51e-05	5.01e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CAV1—ovarian cancer	1.5e-05	4.97e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CG—ovarian cancer	1.5e-05	4.96e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CB—ovarian cancer	1.49e-05	4.93e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MYC—ovarian cancer	1.49e-05	4.92e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—STAT3—ovarian cancer	1.46e-05	4.83e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NRAS—ovarian cancer	1.46e-05	4.82e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MAPK1—ovarian cancer	1.46e-05	4.81e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EGFR—ovarian cancer	1.45e-05	4.81e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.43e-05	4.74e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MAPK3—ovarian cancer	1.4e-05	4.61e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.38e-05	4.56e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KRAS—ovarian cancer	1.37e-05	4.55e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CG—ovarian cancer	1.37e-05	4.52e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PTEN—ovarian cancer	1.37e-05	4.52e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MYC—ovarian cancer	1.36e-05	4.49e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.35e-05	4.46e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MAPK1—ovarian cancer	1.33e-05	4.39e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—EGFR—ovarian cancer	1.33e-05	4.39e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CD—ovarian cancer	1.32e-05	4.36e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PTEN—ovarian cancer	1.29e-05	4.26e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CAV1—ovarian cancer	1.28e-05	4.24e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CA—ovarian cancer	1.26e-05	4.18e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—KRAS—ovarian cancer	1.25e-05	4.15e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.25e-05	4.14e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—TYMS—ovarian cancer	1.23e-05	4.06e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.23e-05	4.05e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TP53—ovarian cancer	1.22e-05	4.04e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.21e-05	4.01e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1.2e-05	3.98e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CG—ovarian cancer	1.17e-05	3.87e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—HRAS—ovarian cancer	1.17e-05	3.86e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CA—ovarian cancer	1.15e-05	3.81e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CB—ovarian cancer	1.15e-05	3.8e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL6—ovarian cancer	1.12e-05	3.7e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—HRAS—ovarian cancer	1.07e-05	3.52e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.06e-05	3.5e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.05e-05	3.47e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AKT1—ovarian cancer	1.03e-05	3.41e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CD—ovarian cancer	1.03e-05	3.4e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—IL6—ovarian cancer	1.02e-05	3.37e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PTEN—ovarian cancer	9.93e-06	3.28e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CAV1—ovarian cancer	9.9e-06	3.27e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CA—ovarian cancer	9.65e-06	3.19e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—AKT1—ovarian cancer	9.41e-06	3.11e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PTEN—ovarian cancer	9.14e-06	3.02e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CA—ovarian cancer	9.08e-06	3e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PTEN—ovarian cancer	9.06e-06	2.99e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	9.02e-06	2.98e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CB—ovarian cancer	8.96e-06	2.96e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	7.93e-06	2.62e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—AKT1—ovarian cancer	7.88e-06	2.61e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PTEN—ovarian cancer	7.74e-06	2.56e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—AKT1—ovarian cancer	7.42e-06	2.45e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CA—ovarian cancer	7.01e-06	2.32e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	6.91e-06	2.29e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CA—ovarian cancer	6.44e-06	2.13e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CA—ovarian cancer	6.39e-06	2.11e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PTEN—ovarian cancer	5.97e-06	1.98e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—AKT1—ovarian cancer	5.72e-06	1.89e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CA—ovarian cancer	5.46e-06	1.81e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—AKT1—ovarian cancer	5.26e-06	1.74e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—AKT1—ovarian cancer	5.22e-06	1.73e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—AKT1—ovarian cancer	4.46e-06	1.47e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	4.21e-06	1.39e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—AKT1—ovarian cancer	3.44e-06	1.14e-05	CbGpPWpGaD
